Screener
McKesson MCK Prescription Technology Solutions — Payments for Restructuring
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRestructuring.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 (1) | $18 | $3 | $10 | $13 | $44 |
| Restructuring, impairment, and related charges, net | 2 | 61 | 23 | 50 | 136 |
| Non-cash charges | (1) | (40) | — | (6) | (47) |
| Cash payments | (3) | — | (16) | (40) | (59) |
| Balance, June 30, 2026 (2) | $16 | $24 | $17 | $17 | $74 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's prescription technology solutions — payments for restructuring?
- McKesson (MCK) reported prescription technology solutions — payments for restructuring of $0 in Q2 2026.
- What is the long-term trend for McKesson's prescription technology solutions — payments for restructuring?
- Over 2 years (2023 to 2025), McKesson's prescription technology solutions — payments for restructuring has grown at a -24.4% compound annual growth rate (CAGR), from $7M to $4M.
- What does prescription technology solutions — payments for restructuring mean?
- Represents the actual cash outflows made to settle liabilities associated with restructuring activities in the Prescription Technology Solutions segment. This metric tracks the cash impact of previously announced organizational changes.
Ask your AI about McKesson's prescription technology solutions — payments for restructuring.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude